Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

This dataset reports the daily reported number of the 7-day moving average rates of Deaths involving COVID-19 by vaccination status and by age group. Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak. Effective November 14, 2024 this page will no longer be updated. Information about COVID-19 and other respiratory viruses is available on Public Health Ontario’s interactive respiratory virus tool: https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool Data includes: * Date on which the death occurred * Age group * 7-day moving average of the last seven days of the death rate per 100,000 for those not fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those vaccinated with at least one booster ##Additional notes As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm. As of January 12, 2024, data from the date of January 1, 2024 onwards reflect updated population estimates. This update specifically impacts data for the 'not fully vaccinated' category. On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023. CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags. The data does not include vaccination data for people who did not provide consent for vaccination records to be entered into the provincial COVaxON system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information in COVaxON. “Not fully vaccinated” category includes people with no vaccine and one dose of double-dose vaccine. “People with one dose of double-dose vaccine” category has a small and constantly changing number. The combination will stabilize the results. Spikes, negative numbers and other data anomalies: Due to ongoing data entry and data quality assurance activities in Case and Contact Management system (CCM) file, Public Health Units continually clean up COVID-19, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes, negative numbers and current totals being different from previously reported case and death counts. Public Health Units report cause of death in the CCM based on information available to them at the time of reporting and in accordance with definitions provided by Public Health Ontario. The medical certificate of death is the official record and the cause of death could be different. Deaths are defined per the outcome field in CCM marked as “Fatal”. Deaths in COVID-19 cases identified as unrelated to COVID-19 are not included in the Deaths involving COVID-19 reported. Rates for the most recent days are subject to reporting lags All data reflects totals from 8 p.m. the previous day. This dataset is subject to change.

NOTE: This dataset has been retired and marked as historical-only. Weekly rates of COVID-19 cases, hospitalizations, and deaths among people living in Chicago by vaccination status and age. Rates for fully vaccinated and unvaccinated begin the week ending April 3, 2021 when COVID-19 vaccines became widely available in Chicago. Rates for boosted begin the week ending October 23, 2021 after booster shots were recommended by the Centers for Disease Control and Prevention (CDC) for adults 65+ years old and adults in certain populations and high risk occupational and institutional settings who received Pfizer or Moderna for their primary series or anyone who received the Johnson & Johnson vaccine. Chicago residency is based on home address, as reported in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) and Illinois National Electronic Disease Surveillance System (I-NEDSS). Outcomes: • Cases: People with a positive molecular (PCR) or antigen COVID-19 test result from an FDA-authorized COVID-19 test that was reported into I-NEDSS. A person can become re-infected with SARS-CoV-2 over time and so may be counted more than once in this dataset. Cases are counted by week the test specimen was collected. • Hospitalizations: COVID-19 cases who are hospitalized due to a documented COVID-19 related illness or who are admitted for any reason within 14 days of a positive SARS-CoV-2 test. Hospitalizations are counted by week of hospital admission. • Deaths: COVID-19 cases who died from COVID-19-related health complications as determined by vital records or a public health investigation. Deaths are counted by week of death. Vaccination status: • Fully vaccinated: Completion of primary series of a U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccine at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Boosted: Fully vaccinated with an additional or booster dose of any FDA-authorized or approved COVID-19 vaccine received at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Unvaccinated: No evidence of having received a dose of an FDA-authorized or approved vaccine prior to a positive test. CLARIFYING NOTE: Those who started but did not complete all recommended doses of an FDA-authorized or approved vaccine prior to a positive test (i.e., partially vaccinated) are excluded from this dataset. Incidence rates for fully vaccinated but not boosted people (Vaccinated columns) are calculated as total fully vaccinated but not boosted with outcome divided by cumulative fully vaccinated but not boosted at the end of each week. Incidence rates for boosted (Boosted columns) are calculated as total boosted with outcome divided by cumulative boosted at the end of each week. Incidence rates for unvaccinated (Unvaccinated columns) are calculated as total unvaccinated with outcome divided by total population minus cumulative boosted, fully, and partially vaccinated at the end of each week. All rates are multiplied by 100,000. Incidence rate ratios (IRRs) are calculated by dividing the weekly incidence rates among unvaccinated people by those among fully vaccinated but not boosted and boosted people. Overall age-adjusted incidence rates and IRRs are standardized using the 2000 U.S. Census standard population. Population totals are from U.S. Census Bureau American Community Survey 1-year estimates for 2019. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. This dataset reflects data known to CDPH at the time when the dataset is updated each week. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. For all datasets related to COVID-19, see https://data.cityofchic

Note: This dataset is no longer being updated due to the end of the COVID-19 Public Health Emergency.

The California Department of Public Health (CDPH) is identifying vaccination status of COVID-19 cases, hospitalizations, and deaths by analyzing the state immunization registry and registry of confirmed COVID-19 cases. Post-vaccination cases are individuals who have a positive SARS-Cov-2 molecular test (e.g. PCR) at least 14 days after they have completed their primary vaccination series.

Tracking cases of COVID-19 that occur after vaccination is important for monitoring the impact of immunization campaigns. While COVID-19 vaccines are safe and effective, some cases are still expected in persons who have been vaccinated, as no vaccine is 100% effective. For more information, please see https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/Post-Vaccine-COVID19-Cases.aspx

Post-vaccination infection data is updated monthly and includes data on cases, hospitalizations, and deaths among the unvaccinated and the vaccinated. Partially vaccinated individuals are excluded. To account for reporting and processing delays, there is at least a one-month lag in provided data (for example data published on 9/9/22 will include data through 7/31/22).

Notes:

• On September 9, 2022, the post-vaccination data has been changed to compare unvaccinated with those with at least a primary series completed for persons age 5+. These data will be updated monthly (first Thursday of the month) and include at least a one month lag.

• On February 2, 2022, the post-vaccination data has been changed to distinguish between vaccination with a primary series only versus vaccinated and boosted. The previous dataset has been uploaded as an archived table. Additionally, the lag on this data has been extended to 14 days.

• On November 29, 2021, the denominator for calculating vaccine coverage has been changed from age 16+ to age 12+ to reflect new vaccine eligibility criteria. The previous dataset based on age 16+ denominators has been uploaded as an archived table.

Analysis of ‘COVID vaccination vs. mortality ’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://www.kaggle.com/sinakaraji/covid-vaccination-vs-death on 12 November 2021.

--- Dataset description provided by original source is as follows ---

Context

The COVID-19 outbreak has brought the whole planet to its knees.More over 4.5 million people have died since the writing of this notebook, and the only acceptable way out of the disaster is to vaccinate all parts of society. Despite the fact that the benefits of vaccination have been proved to the world many times, anti-vaccine groups are springing up all over the world. This data set was generated to investigate the impact of coronavirus vaccinations on coronavirus mortality.

Content

country	iso_code	date	total_vaccinations	people_vaccinated	people_fully_vaccinated	New_deaths	population	ratio
country name	iso code for each country	date that this data belong	number of all doses of COVID vaccine usage in that country	number of people who got at least one shot of COVID vaccine	number of people who got full vaccine shots	number of daily new deaths	2021 country population	% of vaccinations in that country at that date = people_vaccinated/population * 100

Data Collection

This dataset is a combination of the following three datasets:

1.https://www.kaggle.com/gpreda/covid-world-vaccination-progress

2.https://covid19.who.int/WHO-COVID-19-global-data.csv

3.https://www.kaggle.com/rsrishav/world-population

you can find more detail about this dataset by reading this notebook:

https://www.kaggle.com/sinakaraji/simple-linear-regression-covid-vaccination

Countries in this dataset:

Afghanistan	Albania	Algeria	Andorra	Angola
Anguilla	Antigua and Barbuda	Argentina	Armenia	Aruba
Australia	Austria	Azerbaijan	Bahamas	Bahrain
Bangladesh	Barbados	Belarus	Belgium	Belize
Benin	Bermuda	Bhutan	Bolivia (Plurinational State of)	Brazil
Bosnia and Herzegovina	Botswana	Brunei Darussalam	Bulgaria	Burkina Faso
Cambodia	Cameroon	Canada	Cabo Verde	Cayman Islands
Central African Republic	Chad	Chile	China	Colombia
Comoros	Cook Islands	Costa Rica	Croatia	Cuba
Curaçao	Cyprus	Denmark	Djibouti	Dominica
Dominican Republic	Ecuador	Egypt	El Salvador	Equatorial Guinea
Estonia	Ethiopia	Falkland Islands (Malvinas)	Fiji	Finland
France	French Polynesia	Gabon	Gambia	Georgia
Germany	Ghana	Gibraltar	Greece	Greenland
Grenada	Guatemala	Guinea	Guinea-Bissau	Guyana
Haiti	Honduras	Hungary	Iceland	India
Indonesia	Iran (Islamic Republic of)	Iraq	Ireland	Isle of Man
Israel	Italy	Jamaica	Japan	Jordan
Kazakhstan	Kenya	Kiribati	Kuwait	Kyrgyzstan
Lao People's Democratic Republic	Latvia	Lebanon	Lesotho	Liberia
Libya	Liechtenstein	Lithuania	Luxembourg	Madagascar
Malawi	Malaysia	Maldives	Mali	Malta
Mauritania	Mauritius	Mexico	Republic of Moldova	Monaco
Mongolia	Montenegro	Montserrat	Morocco	Mozambique
Myanmar	Namibia	Nauru	Nepal	Netherlands
New Caledonia	New Zealand	Nicaragua	Niger	Nigeria
Niue	North Macedonia	Norway	Oman	Pakistan
occupied Palestinian territory, including east Jerusalem
Panama	Papua New Guinea	Paraguay	Peru	Philippines
Poland	Portugal	Qatar	Romania	Russian Federation
Rwanda	Saint Kitts and Nevis	Saint Lucia
Saint Vincent and the Grenadines	Samoa	San Marino	Sao Tome and Principe	Saudi Arabia
Senegal	Serbia	Seychelles	Sierra Leone	Singapore
Slovakia	Slovenia	Solomon Islands	Somalia	South Africa
Republic of Korea	South Sudan	Spain	Sri Lanka	Sudan
Suriname	Sweden	Switzerland	Syrian Arab Republic	Tajikistan
United Republic of Tanzania	Thailand	Togo	Tonga	Trinidad and Tobago
Tunisia	Turkey	Turkmenistan	Turks and Caicos Islands	Tuvalu
Uganda	Ukraine	United Arab Emirates	The United Kingdom	United States of America
Uruguay	Uzbekistan	Vanuatu	Venezuela (Bolivarian Republic of)	Viet Nam
Wallis and Futuna	Yemen	Zambia	Zimbabwe

--- Original source retains full ownership of the source dataset ---

Note: In these datasets, a person is defined as up to date if they have received at least one dose of an updated COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that certain groups, including adults ages 65 years and older, receive additional doses.

On 6/16/2023 CDPH replaced the booster measures with a new “Up to Date” measure based on CDC’s new recommendations, replacing the primary series, boosted, and bivalent booster metrics The definition of “primary series complete” has not changed and is based on previous recommendations that CDC has since simplified. A person cannot complete their primary series with a single dose of an updated vaccine. Whereas the booster measures were calculated using the eligible population as the denominator, the new up to date measure uses the total estimated population. Please note that the rates for some groups may change since the up to date measure is calculated differently than the previous booster and bivalent measures.

This data is from the same source as the Vaccine Progress Dashboard at https://covid19.ca.gov/vaccination-progress-data/ which summarizes vaccination data at the county level by county of residence. Where county of residence was not reported in a vaccination record, the county of provider that vaccinated the resident is included. This applies to less than 1% of vaccination records. The sum of county-level vaccinations does not equal statewide total vaccinations due to out-of-state residents vaccinated in California.

These data do not include doses administered by the following federal agencies who received vaccine allocated directly from CDC: Indian Health Service, Veterans Health Administration, Department of Defense, and the Federal Bureau of Prisons.

Totals for the Vaccine Progress Dashboard and this dataset may not match, as the Dashboard totals doses by Report Date and this dataset totals doses by Administration Date. Dose numbers may also change for a particular Administration Date as data is updated.

Previous updates:

• On March 3, 2023, with the release of HPI 3.0 in 2022, the previous equity scores have been updated to reflect more recent community survey information. This change represents an improvement to the way CDPH monitors health equity by using the latest and most accurate community data available. The HPI uses a collection of data sources and indicators to calculate a measure of community conditions ranging from the most to the least healthy based on economic, housing, and environmental measures.

• Starting on July 13, 2022, the denominator for calculating vaccine coverage has been changed from age 5+ to all ages to reflect new vaccine eligibility criteria. Previously the denominator was changed from age 16+ to age 12+ on May 18, 2021, then changed from age 12+ to age 5+ on November 10, 2021, to reflect previous changes in vaccine eligibility criteria. The previous datasets based on age 16+ and age 5+ denominators have been uploaded as archived tables.

• Starting on May 29, 2021 the methodology for calculating on-hand inventory in the shipped/delivered/on-hand dataset has changed. Please see the accompanying data dictionary for details. In addition, this dataset is now down to the ZIP code level.

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes

Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status

Dataset and data visualization details:

These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023.

Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category.

Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis.

Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be

On 6/28/2023, data on cases by vaccination status will be archived and will no longer update.

A. SUMMARY This dataset represents San Francisco COVID-19 positive confirmed cases by vaccination status over time, starting January 1, 2021. Cases are included on the date the positive test was collected (the specimen collection date). Cases are counted in three categories: (1) all cases; (2) unvaccinated cases; and (3) completed primary series cases.

1. All cases: Includes cases among all San Francisco residents regardless of vaccination status.

2. Unvaccinated cases: Cases are considered unvaccinated if their positive COVID-19 test was before receiving any vaccine. Cases that are not matched to a COVID-19 vaccination record are considered unvaccinated.

3. Completed primary series cases: Cases are considered completed primary series if their positive COVID-19 test was 14 days or more after they received their 2nd dose in a 2-dose COVID-19 series or the single dose of a 1-dose vaccine. These are also called “breakthrough cases.”

On September 12, 2021, a new case definition of COVID-19 was introduced that includes criteria for enumerating new infections after previous probable or confirmed infections (also known as reinfections). A reinfection is defined as a confirmed positive PCR lab test more than 90 days after a positive PCR or antigen test. The first reinfection case was identified on December 7, 2021.

Data is lagged by eight days, meaning the most recent specimen collection date included is eight days prior to today. All data updates daily as more information becomes available.

B. HOW THE DATASET IS CREATED Case information is based on confirmed positive laboratory tests reported to the City. The City then completes quality assurance and other data verification processes. Vaccination data comes from the California Immunization Registry (CAIR2). The California Department of Public Health runs CAIR2. Individual-level case and vaccination data are matched to identify cases by vaccination status in this dataset. Case records are matched to vaccine records using first name, last name, date of birth, phone number, and email address.

We include vaccination records from all nine Bay Area counties in order to improve matching rates. This allows us to identify breakthrough cases among people who moved to the City from other Bay Area counties after completing their vaccine series. Only cases among San Francisco residents are included.

C. UPDATE PROCESS Updates automatically at 08:00 AM Pacific Time each day.

D. HOW TO USE THIS DATASET Total San Francisco population estimates can be found in a view based on the San Francisco Population and Demographic Census dataset. These population estimates are from the 2016-2020 5-year American Community Survey (ACS). To identify total San Francisco population estimates, filter the view on “demographic_category_label” = “all ages”.

Population estimates by vaccination status are derived from our publicly reported vaccination counts, which can be found at COVID-19 Vaccinations Given to SF Residents Over Time.

The dataset includes new cases, 7-day average new cases, new case rates, 7-day average new case rates, percent of total cases, and 7-day average percent of total cases for each vaccination category.

New cases are the count of cases where the positive tests were collected on that specific specimen collection date. The 7-day rolling average shows the trend in new cases. The rolling average is calculated by averaging the new cases for a particular day with the prior 6 days.

New case rates are the count of new cases per 100,000 residents in each vaccination status group. The 7-day rolling average shows the trend in case rates. The rolling average is calculated by averaging the case rate for a particular day with the prior six days. Percent of total new cases shows the percent of all cases on each day that were among a particular vaccination status.

Here is more information on how each case rate is calculated:

1. The case rate for all cases is equal to the number of new cases among all residents divided by the estimated total resident population.

2. Unvaccinated case rates are equal to the number of new cases among unvaccinated residents divided by the estimated number of unvaccinated residents. The estimated number of unvaccinated residents is calculated by subtracting the number of residents that have received at least one dose of a vaccine from the total estimated resident population.

3. Completed primary series case rates are equal to the number of new cases among completed primary series residents divided by the estimated number of completed primary series residents. The estimated number of completed primary series residents is calculated by taking the number of residents who have completed their primary series over time and adding a 14-day delay to the “date_administered” column, to align with the definition of “Completed primary series cases” above.

E. CHANGE LOG

• 6/28/2023 - data on cases by vaccination status are no longer being updated. This data is currently through 6/20/2023 (as of 6/28/2023) and will not include any new data after this date.
  
• 4/6/2023 - the State implemented system updates to improve the integrity of historical data.
• 2/21/2023 - system updates to improve reliability and accuracy of cases data were implemented.
• 1/31/2023 - updated “sf_population” column to reflect the 2020 Census Bureau American Community Survey (ACS) San Francisco Population estimates.
• 1/31/2023 - renamed column “last_updated_at” to “data_as_of”.
• 1/22/2022 - system updates to improve timeliness and accuracy of cases and deaths data were implemented.
• 7/15/2022 - reinfections added to cases dataset. See section SUMMARY for more information on how reinfections are identified.
• 7/15/2022 - references to “fully vaccinated” replaced with “completed primary series” in column “vaccination_status".
• 7/15/2022 - rows with “partially vaccinated” in column “vaccination_status” removed from dataset.

This dataset reports the daily reported number of the 7-day moving average rates of Deaths involving COVID-19 by vaccination status and by age group. Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak. Data includes: * Date on which the death occurred * Age group * 7-day moving average of the last seven days of the death rate per 100,000 for those not fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those vaccinated with at least one booster ##Additional notes As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm. As of January 12, 2024, data from the date of January 1, 2024 onwards reflect updated population estimates. This update specifically impacts data for the 'not fully vaccinated' category. On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023. CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags. The data does not include vaccination data for people who did not provide consent for vaccination records to be entered into the provincial COVaxON system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information in COVaxON. “Not fully vaccinated” category includes people with no vaccine and one dose of double-dose vaccine. “People with one dose of double-dose vaccine” category has a small and constantly changing number. The combination will stabilize the results. Spikes, negative numbers and other data anomalies: Due to ongoing data entry and data quality assurance activities in Case and Contact Management system (CCM) file, Public Health Units continually clean up COVID-19, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes, negative numbers and current totals being different from previously reported case and death counts. Public Health Units report cause of death in the CCM based on information available to them at the time of reporting and in accordance with definitions provided by Public Health Ontario. The medical certificate of death is the official record and the cause of death could be different. Deaths are defined per the outcome field in CCM marked as “Fatal”. Deaths in COVID-19 cases identified as unrelated to COVID-19 are not included in the Deaths involving COVID-19 reported. Rates for the most recent days are subject to reporting lags All data reflects totals from 8 p.m. the previous day. This dataset is subject to change.

Estimates of the risk of all-cause and cardiac death in the 12 weeks after vaccination or positive SARS-CoV-2 test compared with subsequent weeks for people aged 12 to 29 years in England using two sources of mortality data: ONS death registrations and deaths recorded in Hospital Episode Statistics. 8 December 2020 to 25 May 2022. Experimental Statistics.

While mass vaccination campaigns against COVID-19 have inoculated almost 200 million Americans and billions more worldwide, significant pockets of vaccine hesitancy remain. Research has firmly established that vaccine efficacy is an important driver of public vaccine acceptance and choice. However, current vaccines offer widely varying levels of protection against different adverse health outcomes of COVID-19. This study employs an experiment embedded on a survey of 1,194 US adults in June 2021 to examine how communications about vaccine efficacy affect vaccine choice. The experiment manipulated how vaccine efficacy was defined across four treatments: (1) protection against symptomatic infection; (2) protection against severe illness; (3) protection against hospitalization/death; (4) efficacy data on all three metrics. The control group received no efficacy information. Subjects were asked to choose between a pair of vaccines—a one-dose viral vector vaccine or two-dose mRNA vaccine—whose efficacy data varied across the four experimental treatment groups. Efficacy data for each vaccine on each dimension were adapted from clinical trial data on the Johnson & Johnson/Janssen and Pfizer/BioNTech vaccines. Among all respondents, only modest preference gaps between the two vaccines emerged in the control group and when the two vaccines’ roughly equivalent efficacy data against hospitalization and death were reported. Strong preferences for a two-dose mRNA vaccine emerged in treatments where its higher efficacy against symptomatic or severe illness was reported, as well as in the treatment where data on all three efficacy criteria were reported. Unvaccinated respondents preferred a one-dose viral vector vaccine when only efficacy data against hospitalization or death was presented. Black and Latino respondents were significantly more likely to choose the one-shot viral vector vaccine in the combined efficacy treatment than were whites. Results speak to the importance of understanding how communications about vaccine efficacy affect public preferences in an era of increasing uncertainty about efficacy against variants.

The California Department of Public Health (CDPH) is identifying vaccination status of COVID-19 cases, hospitalizations, and deaths by analyzing the state immunization registry and registry of confirmed COVID-19 cases. Post-vaccination cases are individuals who have a positive SARS-Cov-2 molecular test (e.g. PCR) at least 14 days after they have completed their primary vaccination series or 14 days after they have completed their booster or additional dose.

Tracking cases of COVID-19 that occur after vaccination and/or boosters is important for monitoring the impact of immunization campaigns. While COVID-19 vaccines are safe and effective, some cases are still expected in persons who have been vaccinated, as no vaccine is 100% effective. For more information, please see https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID-19/Post-Vaccine-COVID19-Cases.aspx

Post-vaccination infection data is updated weekly and includes data on cases, hospitalizations, and deaths among the unvaccinated, those vaccinated with a primary series only, and those with an additional or booster dose. Partially vaccinated individuals are excluded. To account for reporting and processing delays, there is a 14 day lag in provided data (for example, for data through 1/23/2022, only data through 1/9/2022 will be made available). For deaths, there is an even greater lag in reporting, so more recent data should be used with caution. For display on the public dashboard, there is an additional 7-day lag for death data (21 days total). Note that this lag is separate from the difference in dates between data processing and updates to the website (in the above example, data through 1/9/2022 would be updated on the website on 2/2/2022).

Notes:

• On February 2, 2022, the post-vaccination data has been changed to distinguish between vaccination with a primary series only versus vaccinated and boosted. The previous dataset has been uploaded as an archived table. Additionally, the lag on this data has been extended to 14 days.

• On November 29, 2021, the denominator for calculating vaccine coverage has been changed from age 16+ to age 12+ to reflect new vaccine eligibility criteria. The previous dataset based on age 16+ denominators has been uploaded as an archived table.

BackgroundData on allergic reactions after the administration of coronavirus disease (COVID-19) vaccines are limited. Our aim is to analyze reports of allergic reactions after COVID-19 vaccine administration.MethodsThe Vaccine Adverse Event Reporting System database was searched for reported allergic reactions after the administration of any of the COVID-19 vaccines from December 2020 to June 2021. After data mapping, the demographic and clinical characteristics of the reported cases were analyzed. Potential factors associated with anaphylaxis were evaluated using multivariable logistic regression models.ResultsIn total, 14,611 cases were reported. Most cases of allergic reactions comprised women (84.6%) and occurred after the first dose of the vaccine (63.6%). Patients who experienced anaphylaxis were younger (mean age 45.11 ± 5.6 vs. 47.01 ± 6.3 years, P < 0.001) and had a higher prevalence of a history of allergies, allergic rhinitis, asthma, and anaphylaxis than those who did not (P < 0.05). A history of allergies (odds ratio (OR) 1.632, 95% confidence interval (CI) 1.467–1.816, P < 0.001), asthma (OR 1.908, 95%CI 1.677–2.172, P < 0.001), and anaphylaxis (OR 7.164, 95%CI 3.504–14.646, P < 0.001) were potential risk factors for anaphylaxis. Among the 8,232 patients with reported outcomes, 16 died.ConclusionsFemale predominance in allergic reaction cases after the receipt of COVID-19 vaccines was observed. Previous histories of allergies, asthma, or anaphylaxis were risk factors for anaphylaxis post-vaccination. People with these risk factors should be monitored more strictly after COVID-19 vaccination.

Source of datasets:

WHO COVID-19 Dashboard. Geneva: World Health Organization, 2020. Available online: https://covid19.who.int/ (last cited: 23 Aug 2021)

Our World in Data. (n.d.). COVID-19 vaccine doses administered per 100 people. Available online: https://ourworldindata.org/grapher/covid-vaccination-doses-per-capita. (last cited: 23 Aug 2021)

Population by Country - 2020, provided by Tanu N Prabhu

The code can be found in: https://www.kaggle.com/steviewooo/covid-analysis-data-cleaning

Attitudes on vaccination against COVID-19. Topics: preferred time for getting vaccinated; importance of each of the following issues with regard to getting vaccinated: vaccine will help to end the pandemic, vaccine will protect respondent from getting COVID-19, vaccine will protect relatives and others from getting COVID-19, vaccine will make it possible to resume a more normal professional life, vaccine will make it possible to travel, vaccine will make it possible to meet family and friends, vaccine will make it possible to go to restaurants, cinemas etc.; importance of each of the following issues with regard to not getting vaccinated: pandemic will be over soon, personal risk of being infected is very low, risk posed by COVID-19 in general is exaggerated, worries about side effects of COVID-19 vaccines, vaccines have not been sufficiently tested yet, vaccines are ineffective, against vaccines in general; factors to increase personal willingness of getting vaccinated: more people around doing it, more people have already been vaccinated and we see that there are no major side-effects, people that recommend the vaccines are vaccinated themselves, doctor recommends respondent to do so, vaccines are developed in the European Union, full clarity on how vaccines are being developed, tested and authorized, respondent is very eager to get vaccinated or is already vaccinated, won’t get vaccinated anyway; attitude towards the following statements on the vaccines: benefits outweigh possible risks, vaccines authorised in the European Union are safe, vaccines are being developed, tested and authorised too quickly to be safe, vaccines could have long term side-effects that we do not know yet, a vaccine is the only way to end the pandemic, no understanding why people are reluctant to get vaccinated, serious diseases have disappeared thanks to vaccines; attitude towards the following statements: one can avoid being infected without being vaccinated, public authorities are not sufficiently transparent about COVID-19 vaccines, getting vaccinated against COVID-19 is a civic duty, vaccination should be compulsory, European Union is playing a key role in ensuring access to COVID-19 vaccines in the own country; most trustworthy institutions or persons regarding the provision of information about COVID-19 vaccines; interest in additional information about the following aspects: development, testing, and authorization of COVID-19 vaccines, safety of COVID-19 vaccines, effectiveness of COVID-19 vaccines; satisfaction with the handling of the vaccination strategy by: national government, EU; applicability of the following statements: respondent knows people who have tested positive to COVID-19, respondent knows people who have been ill because of COVID-19, respondent has tested positive to COVID-19, respondent has been ill because of COVID-19, respondent fears to be infected in the future; vaccination of respondent: as a child, as an adult; attitude towards vaccines in general: are safe, are effective. Demography: age; sex; nationality; age at end of education; occupation; professional position; type of community; household composition and household size; region. Additionally coded was: respondent ID; country; device used for interview; nation group; weighting factor. Einstellungen zur Impfung gegen Covid-19. Themen: präferierter Impfzeitpunkt; Wichtigkeit der folgenden Gründe im Hinblick auf die Entscheidung, sich impfen zu lassen: Impfstoff wird bei der Beendigung der Pandemie helfen, Impfstoff wird den/die Befragte/n vor Covid-19 schützen, Impfstoff wird Verwandte und andere vor COVID-19 schützen, Impfstoff wird wieder ein normaleres Berufsleben ermöglichen, Impfstoff wird das Reisen ermöglichen, Impfstoff wird Treffen mit Familie und Freunden ermöglichen, Impfstoff wird Restaurantbesuche und andere Aktivitäten wieder ermöglichen; Wichtigkeit der folgenden Gründe im Hinblick auf die Entscheidung, sich nicht impfen zu lassen: Pandemie wird bald vorbei sein, persönliches Infektionsrisiko ist sehr gering, Risiko durch COVID-19 ist allgemein übertrieben, Sorgen über die Nebenwirkungen von COVID-19-Impfstoffen, Impfstoffe sind noch nicht ausreichend getestet, Impfstoffe sind unwirksam, generelle Ablehnung von Impfungen; Faktoren, die die persönliche Impfbereitschaft erhöhen würden: mehr geimpfte Menschen im Umfeld, viele erfolgreich geimpfte Menschen ohne gravierende Nebenwirkungen, Menschen, die die Impfung empfehlen, sind selbst geimpft, Empfehlung des eigenen Arztes, Entwicklung der Impfstoffe in der Europäischen Union, vollständige Klarheit über Entwicklung, Testung und Zulassung der Impfstoffe, starker Wunsch nach einer Impfung bzw. Befragte/r ist bereits geimpft, keine Impfung geplant; Einstellung zu den folgenden Aussagen zu den Impfstoffen: Vorteile überwiegen mögliche Risiken, in der EU zugelassene Impfstoffe sind sicher, zu schnelle Entwicklung, Testung und Zulassung der Impfstoffe, um sicher zu sein, noch unbekannte potentielle Langzeit-Nebenwirkungen, Impfung ist die einzige Möglichkeit zur Beendigung der Pandemie, kein Verständnis für Impfgegner, Ausrottung ernsthafter Krankheiten durch Impfung; Einstellung zu den folgenden Aussagen: Ansteckung kann auch ohne Impfung vermieden werden, mangelnde Transparenz öffentlicher Behörden in Bezug auf die Corona-Impfstoffe, Impfung gegen COVID-19 ist Bürgerpflicht, Impfung sollte verpflichtend sein, Europäische Union spielt wesentliche Rolle bei der Versorgung des eigenen Landes mit Impfstoff; vertrauenswürdigste Institutionen oder Personen im Hinblick auf die Bereitstellung von Informationen über Corona-Impfstoffe; Interesse an zusätzlichen Informationen über die folgenden Aspekte: Entwicklung, Testung und Zulassung von COVID-19-Impfstoffen, Sicherheit von COVID-19- Impfstoffen, Effektivität von COVID-19-Impfstoffen; Zufriedenheit mit der Umsetzung der Impfstrategie durch: nationale Regierung, EU; Anwendbarkeit der folgenden Aussagen: Befragte/r kennt Menschen mit positivem Corona-Testergebnis, Befragte/r kennt Menschen mit Corona-Erkrankung, Befragte/r hatte positives Corona-Testergebnis, Befragte/r war an Corona erkrankt, Befragte/r fürchtet Ansteckung in der Zukunft; Impfung des/der Befragten als: Kind, Erwachsener; Einstellung zu Impfstoffen im allgemeinen: sind sicher, sind wirksam. Demographie: Alter; Geschlecht; Staatsangehörigkeit; Alter bei Beendigung der Ausbildung; Beruf; berufliche Stellung; Urbanisierungsgrad; Haushaltszusammensetzung und Haushaltsgröße; Region. Zusätzlich verkodet wurde: Befragten-ID; Land; für das Interview genutztes Gerät; Nationengruppe; Gewichtungsfaktor.

This dataset is no longer updated, find vaccination data here From 24 March 2022, Public Health Scotland (PHS) began reporting the number of people who have received a fourth dose of Covid-19 vaccination. Vaccine uptake statistics among care home residents and those who are severely immunosuppressed will be reported initially. PHS will include further updates as the Spring/Summer vaccination programme rolls out. In addition, as part of our continuous review of reporting, PHS made some changes to vaccine uptake statistics. From 24 March 2022, the deceased and those who no longer live in Scotland are no longer be included in vaccine uptake statistics. Historic trend data have been updated to take into account this new methodology for all apart from the Daily Trends by JCVI Priority Group table (more details about the data in this table are below). Scotland level data for all vaccinations administered (i.e. including those who have since died or moved from Scotland) are still available in the Daily Trend of All Vaccinations Delivered in Scotland table. Also from 24 March 2022, Dose 3/Booster doses are termed "Dose 3". To allow new data to be fully processed and available at 14:00, the Daily COVID-19 in Scotland and COVID-19 Vaccination in Scotland datasets will be temporarily unavailable from 12:45 to 14:00. During this window, the datasets will not be visible and any queries made to these datasets will return a 404 - Not found error. At all other times the datasets will be available in full as usual. PHS reviewed the JCVI priority group uptake figures from 18 November 2021, specifically how we derive the numerator and the denominator. The rational for the change is to ensure we report on most up to date living population for each group. For this, the list of individuals in each cohort has been refreshed to be more current. We have also removed individuals who have since died to reflect the current living population. From the 24 March 2022 those who are no longer living in Scotland have also been removed from the numerator and denominator for JCVI priority group uptake figures. This means all the JCVI cohorts and populations have changed for both numerator and denominators on these two dates and care should be taken when interpreting trends. On 08 December 2020, a Coronavirus (COVID-19) vaccine developed by Pfizer BioNTech (Comirnaty) was first used in the UK as part of national immunisation programmes. The AstraZeneca (Spikevax) vaccine was also approved for use in the national programme, and rollout of this vaccine began on 04 January 2021. Moderna (Vaxzevria) vaccine was approved for use on 8 January 2021 and rollout of this vaccine began on 07 April 2021. These vaccines have met strict standards of safety, quality and effectiveness set out by the independent Medicines and Healthcare Products Regulatory Agency (MHRA). Those giving the vaccine to others were the first to receive the vaccination. In the first phase of the programme, NHS Scotland followed the independent advice received from the Joint Committee on Vaccination and Immunisation (JCVI) and prioritised delivery of the vaccine to those with the greatest clinical need, in line with the recommended order of prioritisation. For booster vaccinations a similar approach has been adopted. Definitions used in the vaccine uptake by JCVI priority group resource can be found in the JCVI Priority Group Definitions table. Individuals can appear in more than one JCVI priority group. This dataset provides information on daily number of COVID vaccinations in Scotland. Data on the total number of vaccinations in Scotland is presented by day administered and vaccine type, by age group, by sex, by non-age cohorts and by geographies (NHS Board and Local Authority). As the population in the cohorts can change with time, these will be refined when updated data are available. Additional data sources relating to this topic area are provided in the Links section of the Metadata below. Data visualisation and additional notes are available on the Public Health Scotland - Covid 19 Scotland dashboard.

Einstellungen zur Impfung gegen Covid-19. Themen: präferierter Impfzeitpunkt; Wichtigkeit der folgenden Gründe im Hinblick auf die Entscheidung, sich impfen zu lassen: Impfstoff wird bei der Beendigung der Pandemie helfen, Impfstoff wird den/die Befragte/n vor Covid-19 schützen, Impfstoff wird Verwandte und andere vor COVID-19 schützen, Impfstoff wird wieder ein normaleres Berufsleben ermöglichen, Impfstoff wird das Reisen ermöglichen, Impfstoff wird Treffen mit Familie und Freunden ermöglichen, Impfstoff wird Restaurantbesuche und andere Aktivitäten wieder ermöglichen; Wichtigkeit der folgenden Gründe im Hinblick auf die Entscheidung, sich nicht impfen zu lassen: Pandemie wird bald vorbei sein, persönliches Infektionsrisiko ist sehr gering, Risiko durch COVID-19 ist allgemein übertrieben, Sorgen über die Nebenwirkungen von COVID-19-Impfstoffen, Impfstoffe sind noch nicht ausreichend getestet, Impfstoffe sind unwirksam, generelle Ablehnung von Impfungen; Faktoren, die die persönliche Impfbereitschaft erhöhen würden: mehr geimpfte Menschen im Umfeld, viele erfolgreich geimpfte Menschen ohne gravierende Nebenwirkungen, Menschen, die die Impfung empfehlen, sind selbst geimpft, Empfehlung des eigenen Arztes, Entwicklung der Impfstoffe in der Europäischen Union, vollständige Klarheit über Entwicklung, Testung und Zulassung der Impfstoffe, starker Wunsch nach einer Impfung bzw. Befragte/r ist bereits geimpft, keine Impfung geplant; Einstellung zu den folgenden Aussagen zu den Impfstoffen: Vorteile überwiegen mögliche Risiken, in der EU zugelassene Impfstoffe sind sicher, zu schnelle Entwicklung, Testung und Zulassung der Impfstoffe, um sicher zu sein, noch unbekannte potentielle Langzeit-Nebenwirkungen, Impfung ist die einzige Möglichkeit zur Beendigung der Pandemie, kein Verständnis für Impfgegner, Ausrottung ernsthafter Krankheiten durch Impfung; Einstellung zu den folgenden Aussagen: Ansteckung kann auch ohne Impfung vermieden werden, mangelnde Transparenz öffentlicher Behörden in Bezug auf die Corona-Impfstoffe, Impfung gegen COVID-19 ist Bürgerpflicht, Impfung sollte verpflichtend sein, Europäische Union spielt wesentliche Rolle bei der Versorgung des eigenen Landes mit Impfstoff; vertrauenswürdigste Institutionen oder Personen im Hinblick auf die Bereitstellung von Informationen über Corona-Impfstoffe; Interesse an zusätzlichen Informationen über die folgenden Aspekte: Entwicklung, Testung und Zulassung von COVID-19-Impfstoffen, Sicherheit von COVID-19- Impfstoffen, Effektivität von COVID-19-Impfstoffen; Zufriedenheit mit der Handhabung der Impfstrategie durch: nationale Regierung, EU; Anwendbarkeit der folgenden Aussagen: Befragter kennt Menschen mit positivem Corona-Testergebnis, Befragter kennt Menschen mit Corona-Erkrankung, Befragter hatte positives Corona-Testergebnis, Befragter Corona-Erkrankung, Befragter fürchtet Ansteckung in der Zukunft; Impfung des Befragten als: Kind, Erwachsener; Einstellung zu Impfstoffen im allgemeinen: sind sicher, sind wirksam. Demographie: Alter; Geschlecht; Nationalität; Alter bei Beendigung der Ausbildung; Beruf; berufliche Stellung; Urbanisierungsgrad; Haushaltszusammensetzung und Haushaltsgröße; Region. Zusätzlich verkodet wurde: Befragten-ID; Land; für das Interview genutztes Gerät; Nationengruppe; Gewichtungsfaktor. Attitudes on vaccination against Covid-19. Topics: preferred time for getting vaccinated; importance of each of the following issues with regard to getting vaccinated: vaccine will help to end the pandemic, vaccine will protect respondent from getting Covid-19, vaccine will protect relatives and others from getting Covid-19, vaccine will make it possible to resume a more normal professional life, vaccine will make it possible to travel, vaccine will make it possible to meet family and friends, vaccine will make it possible to go to restaurants, cinemas etc.; importance of each of the following issues with regard to not getting vaccinated: pandemic will be over soon, personal risk of being infected is very low, risk posed by Covid-19 in general is exaggerated, worries about side effects of Covid-19 vaccines, vaccines have not been sufficiently tested yet, vaccines are ineffective, against vaccines in general; factors to increase personal willingness of getting vaccinated: more people around doing it, more people have already been vaccinated and we see that there are no major side-effects, people that recommend the vaccines are vaccinated themselves, doctor recommends respondent to do so, vaccines are developed in the European Union, full clarity on how vaccines are being developed, tested and authorized, respondent is very eager to get vaccinated or is already vaccinated, won’t get vaccinated anyway; attitude towards the following statements on the vaccines: benefits outweigh possible risks, vaccines authorised in the European Union are safe, vaccines are being developed, tested and authorised too quickly to be safe, vaccines could have long term side-effects that we do not know yet, a vaccine is the only way to end the pandemic, no understanding why people are reluctant to get vaccinated, serious diseases have disappeared thanks to vaccines; attitude towards the following statements: one can avoid being infected without being vaccinated, public authorities are not sufficiently transparent about COVID-19 vaccines, getting vaccinated against COVID-19 is a civic duty, vaccination should be compulsory, European Union is playing a key role in ensuring access to COVID-19 vaccines in the own country; most trustworthy institutions or persons regarding the provision of information about COVID-19 vaccines; interest in additional information about the following aspects: development, testing, and authorization of COVID-19 vaccines, safety of COVID-19 vaccines, effectiveness of COVID-19 vaccines; satisfaction with the handling of the vaccination strategy by: national government, EU; applicability of the following statements: respondent knows people who have tested positive to COVID-19, respondent knows people who have been ill because of COVID-19, respondent has tested positive to COVID-19, respondent has been ill because of COVID-19, respondent fears to be infected in the future; vaccination of respondent: as a child, as an adult; attitude towards vaccines in general: are safe, are effective. Demography: age; sex; nationality; age at end of education; occupation; professional position; type of community; household composition and household size; region. Additionally coded was: respondent ID; country; device used for interview; nation group; weighting factor.

COVID-19 Stats & Trends

Context

This dataset seeks to provide insights into what has changed due to policies aimed at combating COVID-19 and evaluate the changes in community activities and its relation to reduced confirmed cases of COVID-19. The reports chart movement trends, compared to an expected baseline, over time (from 2020/02/15 to 2020/02/05) by geography (across 133 countries), as well as some other stats about the country that might help explain the evolution of the disease.

Content

1. Grocery & Pharmacy: Mobility trends for places like grocery markets, food warehouses, farmers' markets, specialty food shops, drug stores, and pharmacies.
2. Parks: Mobility trends for places like national parks, public beaches, marinas, dog parks, plazas, and public gardens.
3. Residential: Mobility trends for places of residence.
4. Retail & Recreation: Mobility trends for places like restaurants, cafes, shopping centers, theme parks, museums, libraries, and movie theaters.
5. Transit stations: Mobility trends for places like public transport hubs such as subway, bus, and train stations.
6. Workplaces: Mobility trends for places of work.
7. Total Cases: Total number of people infected with the SARS-CoV-2.
8. Fatalities: Total number of deaths caused by CoV-19.
9. Government Response Stringency Index: Additive score of nine indicators of government response to CoV-19: School closures, workplace closures, cancellation of public events, public information campaigns, stay at home policies, restrictions on internal movement, international travel controls, testing policy, and contact tracing.
10. COVID-19 Testing: Total number of tests performed.
11. Total Vaccinations: Total number of shots given.
12. Total People Vaccinated: Total number of people given a shot.
13. Total People Fully Vaccinated: Total number of people fully vaccinated (might require two shots of some vaccines).
14. Population: Total number of inhabitants.
15. Population Density per km2: Number of human inhabitants per square kilometer.
16. Health System Index: Overall performance of the health system.
17. Human Development Index (HDI): Summary index based on life expectancy at birth, expected years of schooling for children and mean years of schooling for adults, and GNI per capita.
18. GDP (PPP) per capita: Gross Domestic Product (GDP) per capita based on Purchasing Power Parity (PPP), taking into account the relative cost of local goods, services and inflation rates of the country, rather than using international market exchange rates, which may distort the real differences in per capita income.
19. Elderly Population (percentage): Percentage of the population above the age of 65 years old.

References & Acknowledgements

Bing COVID-19 data. Available at: https://github.com/microsoft/Bing-COVID-19-Data COVID-19 Community Mobility Report. Available at: https://www.google.com/covid19/mobility/ COVID-19: Government Response Stringency Index. Available at: https://ourworldindata.org/grapher/covid-stringency-index Coronavirus (COVID-19) Testing. Available at: https://github.com/owid/covid-19-data/blob/master/public/data/testing/covid-testing-all-observations.csv Coronavirus (COVID-19) Vaccination. Available at: https://raw.githubusercontent.com/owid/covid-19-data/master/public/data/vaccinations/vaccinations.csv List of countries and dependencies by population. Available at: https://www.kaggle.com/tanuprabhu/population-by-country-2020 List of countries and dependencies by population density. Available at: https://www.kaggle.com/tanuprabhu/population-by-country-2020 List of countries by Human Development Index. Available at: http://hdr.undp.org/en/data Measuring Overall Health System Performance. Available at: https://www.who.int/healthinfo/paper30.pdf?ua=1 List of countries by GDP (PPP) per capita. Available at: https://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD List of countries by age structure (65+). Available at: https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS

Authors

• Diogo Silva, up201706892@fe.up.pt